Stayble Therapeutics Ab Stock Cash Flow From Operations
| STABL Stock | SEK 0.57 0.02 3.64% |
Stayble Therapeutics AB fundamentals help investors to digest information that contributes to Stayble Therapeutics' financial success or failures. It also enables traders to predict the movement of Stayble Stock. The fundamental analysis module provides a way to measure Stayble Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stayble Therapeutics stock.
Stayble |
Stayble Therapeutics AB Company Cash Flow From Operations Analysis
Stayble Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Stayble Therapeutics Cash Flow From Operations | (9.63 M) |
Most of Stayble Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stayble Therapeutics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Stayble Therapeutics AB has (9.63 Million) in Cash Flow From Operations. This is 101.83% lower than that of the Healthcare sector and 115.41% lower than that of the Biotechnology industry. The cash flow from operations for all Sweden stocks is 100.99% higher than that of the company.
Stayble Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stayble Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Stayble Therapeutics could also be used in its relative valuation, which is a method of valuing Stayble Therapeutics by comparing valuation metrics of similar companies.Stayble Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Stayble Fundamentals
| Return On Equity | -0.76 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (97.37) % | |||
| Current Valuation | 15.2 M | |||
| Shares Outstanding | 13.85 M | |||
| Shares Owned By Insiders | 32.55 % | |||
| Shares Owned By Institutions | 22.10 % | |||
| Price To Book | 2.85 X | |||
| Price To Sales | 213.81 X | |||
| Gross Profit | 9 K | |||
| EBITDA | (12.03 M) | |||
| Net Income | (12.09 M) | |||
| Cash And Equivalents | 42.71 M | |||
| Cash Per Share | 3.09 X | |||
| Total Debt | 850 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 63.53 X | |||
| Book Value Per Share | 1.43 X | |||
| Cash Flow From Operations | (9.63 M) | |||
| Earnings Per Share | (1.27) X | |||
| Beta | 0.76 | |||
| Market Capitalization | 49.02 M | |||
| Total Asset | 43.64 M | |||
| Z Score | 34.2 | |||
| Net Asset | 43.64 M |
About Stayble Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stayble Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stayble Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stayble Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Stayble Stock Analysis
When running Stayble Therapeutics' price analysis, check to measure Stayble Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stayble Therapeutics is operating at the current time. Most of Stayble Therapeutics' value examination focuses on studying past and present price action to predict the probability of Stayble Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stayble Therapeutics' price. Additionally, you may evaluate how the addition of Stayble Therapeutics to your portfolios can decrease your overall portfolio volatility.